Alivus Life Sciences Ltd
Alivus Life Sciences Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
High single-digit revenue growth is expected for FY'26, with 5% price erosion factored in and 15-17% volume growth anticipated. The company expects high single-digit revenue growth for FY'26, driven by strong expansion in the non-GPL segment and ramp-up of CDMO projects.
From Alivus Life Sciences Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- High single-digit revenue growth is expected for FY'26, with 5% price erosion factored in and 15-17% volume growth anticipated.
- From FY'28-'29, the full capacity of the Solapur plant going live is expected to drive double-digit growth.
- Mature molecules show stable volumes with 2-3% growth, while newer launches and upcoming patent expiries offer significant volume expansion opportunities.
- The CDMO business, despite smaller deal sizes (around $6 million per project), is scaling with steady contributions from current projects and potential new contracts expected in FY'27.
- Continued focus on high-quality, high-margin businesses aims to generate steady cash flow supporting organic and selective inorganic growth.
- Capacity expansions at Dahej, Ankleshwar, and Solapur ensure no capacity constraints for growth over the next 2-3 years.
Profitability & Margins
See what Alivus Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capacity expansion from 1,400 KL to 2,100 KL reactor capacity planned over the next year, including brownfield expansions at Dahej and Ankleshwar, operational from Q2 FY'27, providing runway for at least two years for regulated markets.
- Solapur plant delayed by approximately three months; expected to start operations by July 2026, initially focused on ROW (Rest of World) markets with gradual shift to regulated markets expected by late FY'28.
- Solapur capacity slightly recalibrated from initially planned 600 KL to around 450-500 KL in phase 1, based on product mapping to avoid under-utilization.
- 400 KL capacity allocated specifically for backward integration to secure supply and margin protection for high-value molecules.
- New R&D facility inauguration planned to enhance R&D capabilities focusing on flow chemistry, green chemistry, and particle engineering for new molecule development.
- Management is open to inorganic investments but will pursue only well-defined, value-accretive opportunities cautiously.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alivus Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company currently has five ongoing CDMO projects.
- Projects 4 and 5 together have an expected peak revenue potential of around $12 million, likely reaching this by the second half of FY'27.
- The earlier three CDMO projects generate a run rate of about Rs. 140 crores annually.
- Alivus is in advanced discussions for two additional CDMO projects expected to be locked by Q1 FY'27.
- Anticipated future CDMO contract sizes remain in the $4-6 million range, consistent with current deal sizes.
- Overall, the CDMO order book is growing steadily with new projects expected to contribute incrementally from FY'28 onward.
Alivus Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹689 Cr, net profit ₹163 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alivus Life Sciences Ltd's management said in earlier quarters
- Q2 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
Frequently Asked Questions
What were Alivus Life Sciences Ltd Q3 FY26 results?
High single-digit revenue growth is expected for FY'26, with 5% price erosion factored in and 15-17% volume growth anticipated. The company expects high single-digit revenue growth for FY'26, driven by strong expansion in the non-GPL segment and ramp-up of CDMO projects.
What is Alivus Life Sciences Ltd share price analysis?
Alivus Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 26.3 with a market cap of ₹16,341 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alivus Life Sciences Ltd planning capital expenditure?
Capacity expansion from 1,400 KL to 2,100 KL reactor capacity planned over the next year, including brownfield expansions at Dahej and Ankleshwar, operational from Q2 FY'27, providing runway for at least two years for regulated markets.
Keep Alivus Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.